We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Expert Opinion / Cases · March 18, 2021

Systemic Treatment for Patient With Progressing mCRPC

Written by
Pedro C. Barata MD


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Gregory Lewis

    4 - pembrolizumab In prostate cancer, CDK12 mutations occur in 5%−7% of patients with mCRPC, and most are biallelic inactivations. CDK12-altered/mutated prostate cancer is an aggressive subtype with poor responses and outcomes to hormonal, taxane, and PARP inhibitor therapies. A proportion of these patients may respond favorably to PD-1 inhibitors, which implicates CDK12 deficiency in immunotherapy sensitivity.

  • Juan Artigas

    He should be treated with cabazitaxel and pembrolizumab. CDK12 does not respond to PARP inhibitors.

  • Bahram Mofid

    He should be treared with pembrolizumab

  • Charles Maack

    pembrolizumab as explained by Gregory Lewis

  • Noureddine Benjaafar

    Pembroluzumab or cabazitaxel

  • Jun 20, 2021

    Pending Moderator approval.

Further Reading